<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04394780</url>
  </required_header>
  <id_info>
    <org_study_id>107280</org_study_id>
    <nct_id>NCT04394780</nct_id>
  </id_info>
  <brief_title>Peritoneal Dialysis Fluid Cooling and Cardio-Protective Effects</brief_title>
  <official_title>Pilot Study to Determine Whether Cooled Peritoneal Dialysis Fluid Confers Cardio-Protective Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study team aimed to investigate the relationship between occlusive coronary artery
      disease, myocardial perfusion, and peritoneal dialysate temperature. In addition, the study
      team aimed to identify how abnormal myocardial perfusion in peritoneal dialysis (PD) patients
      is related to occlusive coronary artery disease, to identify factors associated with
      occlusive coronary artery disease in end-stage renal failure patients on PD. Finally, the
      study team identified factors associated with PD induced cardiac injury in end-stage renal
      failure patients on this dialysis modality.

      In order to assess the patients response to physiological stress and the functional relevance
      of their coronary artery disease, patients underwent assessment using dual energy contrast
      enhanced (DCE) CT assessment of coronary arteries and myocardial perfusion. An initial CT
      scan with administration of contrast established baseline information regarding the extent of
      coronary artery disease, fibrosis, and myocardial perfusion at rest. Following this, patients
      underwent pharmacological stress with the administration of adenosine and a repeat CT scan
      established the response to stress in terms of myocardial perfusion. On the second study
      visit patients were started on C-CAPD using peritoneal dialysate cooled to between 32-33
      degrees centigrade, at a pre-determined and precisely controlled temperature for the 4 hour
      duration of C-CAPD. Subsequently, patients were injected with a pharmacological stressor in
      the form of adenosine. They then underwent DCE CT assessment of coronary arteries and
      myocardial perfusion as done in the first visit. The second CT scan took place following a PD
      dwell.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 11, 2016</start_date>
  <completion_date type="Actual">December 18, 2019</completion_date>
  <primary_completion_date type="Actual">July 18, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Every patient underwent peritoneal dialysis at 37 C and then at 32 C one week after.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between occlusive coronary artery disease and myocardial perfusion</measure>
    <time_frame>The day of study visit 1, lasting for approximately 2 hours</time_frame>
    <description>Investigate the correlation between occlusive coronary artery disease, myocardial perfusion, and peritoneal dialysate temperature. Patients will have a CT scan to measure perfusion (mL/min/g) after peritoneal dialysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation between occlusive coronary artery disease and myocardial perfusion</measure>
    <time_frame>The day of study visit 2, lasting for approximately 6 hours</time_frame>
    <description>Investigate the correlation between occlusive coronary artery disease, myocardial perfusion and peritoneal dialysate temperature. Patients will have a CT scan to measure perfusion (mL/min/g) after peritoneal dialysis</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Dialysis; Complications</condition>
  <arm_group>
    <arm_group_label>Peritoneal dialysis at 37 C</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients underwent peritoneal dialysis with the standard temperature.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peritoneal dialysis at 32 C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients started on continuous ambulatory peritoneal dialysis using a peritoneal dialysate cooled to between 32-33 degrees centigrade, at a pre-determined and precisely controlled temperature for the 4 hour duration treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cooling</intervention_name>
    <description>First, patients underwent peritoneal dialysis (PD) at 37 C (standard temperature) and then patients underwent PD cooling. After each PD session, the patient had a CT scan for the study team to study myocardial perfusion at rest and after introduction of a pharmacological stressor.</description>
    <arm_group_label>Peritoneal dialysis at 32 C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients having peritoneal dialysis treatment at least 6 times per week at home and
             followed at the London Health Sciences Centre

          -  Male and female, age=16 years old

          -  Patients listed for renal transplantation

          -  Residual renal function less than or equal to 750 mls per 24 hour period

        Exclusion Criteria:

          -  Not meeting inclusion criteria

          -  Previous adverse reaction to intravenous contrast

          -  Allergy to adenosine - Patients with significant residual renal function (greater than
             750mL/24 hours)

          -  Exposure to peritoneal dialysis for &lt;90 days prior to recruitment

          -  Ongoing spontaneous bacterial peritonitis (SBP)

          -  Severe heart failure (New York Heart Association grade IV) - Cardiac transplant
             recipients

          -  Mental incapacity to consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher W McIntyre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western University</affiliation>
  </overall_official>
  <results_reference>
    <citation>Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003 Mar;63(3):793-808. Review.</citation>
    <PMID>12631061</PMID>
  </results_reference>
  <results_reference>
    <citation>Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced cardiac injury: determinants and associated outcomes. Clin J Am Soc Nephrol. 2009 May;4(5):914-20. doi: 10.2215/CJN.03900808. Epub 2009 Apr 8.</citation>
    <PMID>19357245</PMID>
  </results_reference>
  <results_reference>
    <citation>Boon D, Bos WJ, van Montfrans GA, Krediet RT. Acute effects of peritoneal dialysis on hemodynamics. Perit Dial Int. 2001 Mar-Apr;21(2):166-71.</citation>
    <PMID>11330561</PMID>
  </results_reference>
  <results_reference>
    <citation>Dr√ºeke TB, Massy ZA. Atherosclerosis in CKD: differences from the general population. Nat Rev Nephrol. 2010 Dec;6(12):723-35. doi: 10.1038/nrneph.2010.143. Epub 2010 Oct 26. Review.</citation>
    <PMID>20978469</PMID>
  </results_reference>
  <results_reference>
    <citation>McIntyre CW. Effects of hemodialysis on cardiac function. Kidney Int. 2009 Aug;76(4):371-5. doi: 10.1038/ki.2009.207. Epub 2009 Jun 10. Review.</citation>
    <PMID>19516249</PMID>
  </results_reference>
  <results_reference>
    <citation>Ragosta M, Samady H, Isaacs RB, Gimple LW, Sarembock IJ, Powers ER. Coronary flow reserve abnormalities in patients with diabetes mellitus who have end-stage renal disease and normal epicardial coronary arteries. Am Heart J. 2004 Jun;147(6):1017-23.</citation>
    <PMID>15199350</PMID>
  </results_reference>
  <results_reference>
    <citation>Selby NM, Fialova J, Burton JO, McIntyre CW. The haemodynamic and metabolic effects of hypertonic-glucose and amino-acid-based peritoneal dialysis fluids. Nephrol Dial Transplant. 2007 Mar;22(3):870-9. Epub 2006 Nov 22.</citation>
    <PMID>17121785</PMID>
  </results_reference>
  <results_reference>
    <citation>Verbeke F, Van Biesen W, Pletinck A, Van Bortel LM, Vanholder R. Acute central hemodynamic effects of a volume exchange in peritoneal dialysis. Perit Dial Int. 2008 Mar-Apr;28(2):142-8.</citation>
    <PMID>18332449</PMID>
  </results_reference>
  <results_reference>
    <citation>Selby NM, Fonseca S, Hulme L, Fluck RJ, Taal MW, McIntyre CW. Automated peritoneal dialysis has significant effects on systemic hemodynamics. Perit Dial Int. 2006 May-Jun;26(3):328-35.</citation>
    <PMID>16722025</PMID>
  </results_reference>
  <results_reference>
    <citation>Barnes E, Dutka DP, Khan M, Camici PG, Hall RJ. Effect of repeated episodes of reversible myocardial ischemia on myocardial blood flow and function in humans. Am J Physiol Heart Circ Physiol. 2002 May;282(5):H1603-8.</citation>
    <PMID>11959621</PMID>
  </results_reference>
  <results_reference>
    <citation>McIntyre CW, Burton JO, Selby NM, Leccisotti L, Korsheed S, Baker CS, Camici PG. Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. Clin J Am Soc Nephrol. 2008 Jan;3(1):19-26. Epub 2007 Nov 14.</citation>
    <PMID>18003765</PMID>
  </results_reference>
  <results_reference>
    <citation>Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function. Clin J Am Soc Nephrol. 2009 Dec;4(12):1925-31. doi: 10.2215/CJN.04470709. Epub 2009 Oct 1.</citation>
    <PMID>19808220</PMID>
  </results_reference>
  <results_reference>
    <citation>Erlinge D. A Review of Mild Hypothermia as an Adjunctive Treatment for ST-Elevation Myocardial Infarction. Ther Hypothermia Temp Manag. 2011;1(3):129-41. doi: 10.1089/ther.2011.0008.</citation>
    <PMID>24717042</PMID>
  </results_reference>
  <results_reference>
    <citation>G√∂tberg M, Olivecrona GK, Engblom H, Ugander M, van der Pals J, Heiberg E, Arheden H, Erlinge D. Rapid short-duration hypothermia with cold saline and endovascular cooling before reperfusion reduces microvascular obstruction and myocardial infarct size. BMC Cardiovasc Disord. 2008 Apr 10;8:7. doi: 10.1186/1471-2261-8-7.</citation>
    <PMID>18402663</PMID>
  </results_reference>
  <results_reference>
    <citation>Chopp M, Knight R, Tidwell CD, Helpern JA, Brown E, Welch KM. The metabolic effects of mild hypothermia on global cerebral ischemia and recirculation in the cat: comparison to normothermia and hyperthermia. J Cereb Blood Flow Metab. 1989 Apr;9(2):141-8.</citation>
    <PMID>2921288</PMID>
  </results_reference>
  <results_reference>
    <citation>Jefferies HJ, Burton JO, McIntyre CW. Individualised dialysate temperature improves intradialytic haemodynamics and abrogates haemodialysis-induced myocardial stunning, without compromising tolerability. Blood Purif. 2011;32(1):63-8. doi: 10.1159/000324199. Epub 2011 Feb 24.</citation>
    <PMID>21346338</PMID>
  </results_reference>
  <results_reference>
    <citation>Odudu A, Eldehni MT, McCann GP, McIntyre CW. Randomized Controlled Trial of Individualized Dialysate Cooling for Cardiac Protection in Hemodialysis Patients. Clin J Am Soc Nephrol. 2015 Aug 7;10(8):1408-17. doi: 10.2215/CJN.00200115. Epub 2015 May 11.</citation>
    <PMID>25964310</PMID>
  </results_reference>
  <results_reference>
    <citation>Eldehni MT, Odudu A, McIntyre CW. Randomized clinical trial of dialysate cooling and effects on brain white matter. J Am Soc Nephrol. 2015 Apr;26(4):957-65. doi: 10.1681/ASN.2013101086. Epub 2014 Sep 18.</citation>
    <PMID>25234925</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 6, 2020</study_first_submitted>
  <study_first_submitted_qc>May 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Chris McIntyre</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>cooling</keyword>
  <keyword>peritoneal dialysis</keyword>
  <keyword>myocardial perfusion</keyword>
  <keyword>myocardial heterogeneity</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We don't share participant data with other researchers except our team</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

